Project Grant R01HL172887
Award Date
1/15/25
Completion Date
11/30/28
Dollars Obligated
$1.6M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
The federal Project Grant award R01HL176322, totaling $1,485,606.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The purpose of the grant is to study the role of lipoprotein(a) (Lp(a)) in increasing the risk of atherosclerotic cardiovascular disease (ASCVD) among people living with HIV (PWH). The project aims to: 1) establish Lp(a)-specific ASCVD risk thresholds in PWH, 2) explore mechanisms by which...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $506,984 to the University of Pittsburgh to investigate the role of the LRP1 gene in the development of congenital heart defects. The research aims to: Examine how LRP1 deficiency in cardiac neural crest cells and their migratory pathways impacts outflow tract alignment and atrioventricular cushion development using in vitro and in vivo...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award to the University of California, Los Angeles (UCLA) aims to: 1) identify novel cholesterol-responsive proteins in the vasculature, 2) define molecular mechanisms whereby membrane cholesterol...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $179,280 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The 5-year grant, which began on July 1, 2024, aims to address disparities in polygenic risk scores for coronary heart disease across diverse populations. The key objectives are to: 1) Explore population-specific differences in...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on defining the role of the PLA2G12B protein in the assembly, metabolism, and cardiovascular disease risk of apolipoprotein B (apoB)-containing lipoproteins. The $603,632 award, granted on March 15, 2025, supports research by The Johns Hopkins University to leverage recent findings on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $267,310 to The Trustees of the University of Pennsylvania to investigate ancestry-specific genetic variations associated with heart, lung, blood, and sleep (HLBS) disorders. The key objectives are to: Curate a list of African American-specific predicted loss-of-function and missense genetic variants, and then characterize the...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $2,000,032 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University. The grant, spanning July 1, 2024 to April 30, 2028, will support research to determine how the LRP5 protein transports polyunsaturated fatty acids (PUFAs) and the importance of LRP5-transported PUFAs in regulating neutrophil activities and inflammation-related diseases,...
The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research Program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of an advanced analytical testing device to quantitatively characterize lipoprotein particles in blood. Lipoproteins are key indicators of cardiovascular disease risk, as certain classes can contribute to the buildup...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,665 to the New York Genome Center, Inc. (NYGC) for research to address key challenges in cardiovascular disease (CVD) genetics. The project aims to develop scalable methods to identify causal genetic variants, determine relevant cell types, and map target genes modulated by CVD variants. Key activities include: 1)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,181,177 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to conduct research on the mechanisms of nonvesicular cholesterol transport. The 4-year award, effective August 1, 2024 through May 31, 2028, will support three specific aims: 1) identifying new proteins involved in nonvesicular lipid transport, 2) defining the physiological functions of these...